We have recently identified ␣-galactosylceramide (␣-GalCer) as a specific ligand for an invariant V␣14͞ V␤8.2 T cell receptor exclusively expressed on the majority of V␣14 NKT cells, a novel subset of lymphocytes. Here, we report that ␣-GalCer selectively activates V␣14 NKT cells resulting in prevention of tumor metastasis. The effector mechanisms of the ligand-activated V␣14 NKT cells seem to be mediated by natural killer (NK)-like nonspecific cytotoxicity. Indeed, the cytotoxic index obtained by ␣-GalCeractivated V␣14 NKT cells was reduced by the addition of cold target tumor cells or by treatment with concanamycin A, which inhibits activation and secretion of perforin, but not by mAbs against molecules involved in the NKT cell recognition and conventional cytotoxicity, such as CD1d, V␤8, NK1.1, Ly49C, Fas, or Fas ligand. These results suggest that the ligand-activated V␣14 NKT cells kill tumor cells directly through a CD1d͞V␣14 T cell receptor-independent, NK-like mechanism.
A novel lymphoid lineage, V␣14 natural killer (NK) T cells, distinct from other lymphoid cells including T cells, B cells, and NK cells, is characterized by the early development at day 9.5 of gestation before thymus formation (1) and also by coexpression of the NK receptor and a single, invariant T cell receptor (TCR) encoded by V␣14 and J␣281 gene segments (2) (3) (4) in association with a highly skewed set of V␤s, mainly V␤8.2 (5) (6) (7) (8) (9) (10) (11) (12) (13) . Moreover, the generation of V␣14 NKT cells is exclusively dependent on the expression of the invariant V␣14 TCR as evidenced by the fact that V␣14 NKT cells do not develop in the invariant V␣14 TCR-deficient mice (14) and that the forced expression of the invariant V␣14 TCR leads exclusively to V␣14 NKT cell generation and blocks conventional T cell development (15, 16) .
Although physiological functions of V␣14 NKT cells remain to be elucidated, the extensive analysis has shown that V␣14 NKT cells are able to mediate allograft bone marrow rejection (17) , control autoimmune disease development (18, 19) , and produce large amounts of both interleukin 4 (IL-4) and interferon ␥ (16, 20, 21) . These findings suggest that V␣14-NKT cells play complicated roles in regulating immune responses more than simply as IL-4 or interferon ␥ providers for Th2 or Th1 cell development, respectively, so far reported (22, 23) . In addition, we have demonstrated recently that V␣14 NKT cells are a primary target of IL-12 and exert a major effector function in IL-12-mediated tumor rejection (14) .
A ligand for the invariant V␣14͞V␤8.2 TCR exclusively expressed on V␣14 NKT cells has been identified recently to be ␣-galactosylceramide (␣-GalCer) (16) . In addition, ␣-GalCer is presented by a monomorphic non-majorhistocompatibility gene complex (non-MHC) class Ib molecule, CD1d, expressed on dendritic cells (DC), and the ligand͞CD1 complex selectively stimulates to proliferate V␣14 NKT cells but not other lymphocytes only if costimulatory signals generated by CD40͞CD40 ligand and B7͞ CD28 interactions are provided (16) . The results suggest that activation mechanisms of V␣14 NKT cells are similar to those of conventional T cells. However the effector mechanisms of V␣14 NKT cells after activation with ␣-GalCer have not yet been determined. Here, we demonstrate that one of the effector functions of ␣-GalCer-activated V␣14 NKT cells is a target tumor cell lysis mediated by a TCRindependent, NK-like nonspecific mechanism with perforin.
MATERIALS AND METHODS
Mice. V␣14 NKT-deficient (J␣281 Ϫ͞Ϫ ) mice were established by specific deletion of the J␣281 gene segment with homologous recombination and aggregation chimera techniques (14) . In these mice, only V␣14 NKT cells are not generated, whereas other lymphoid populations, T cells, B cells, and NK cells remain intact. The V␣14 NKT-deficient (J␣281 Ϫ͞Ϫ ) mice were backcrossed three times with C57BL͞6 mice (14) . V␣14 NKT (RAG Ϫ͞Ϫ ͞V␣14tg V␤8.2tg; tg, transgenic) mice with a C57BL͞6 background were established by mating RAG Ϫ͞Ϫ ͞V␤8.2tg mice and RAG Ϫ͞Ϫ ͞V␣14tg mice as described (16) . In the V␣14 NKT mice, only transgenic TCR␣␤ (V␣14tg and V␤8.2tg) are expressed and result in preferential development of V␣14 NKT cells with no detectable number of T cells or NK cells (16) . Pathogen-free C57BL͞6 mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). All mice used in this study were maintained in specific pathogen-free conditions.
Evaluation of the Severity of Hepatic Metastasis. B16 melanoma cells (H-2 b , 3 ϫ 10 6 per mouse) were injected into the spleen of young adult wild-type, V␣14 NKT-deficient, and V␣14 NKT mice. Then, ␣-GalCer (100 g͞kg) or control vehicle was injected intraperitoneally on days 1, 5, and 9. The treated mice were sacrificed on day 14, and their livers were photographed and subjected to quantitation of GM3 melanoma antigens (24) (25) (26) .
Quantitation of GM3 Melanoma Antigen in Metastatic Liver. For measurement of a melanoma antigen (GM3 ganglioside), each liver was homogenized as described (24, 25) . The homogenates of normal or metastatic livers (50 mg) or B16 melanoma cells were treated with 1 ml of extraction buffer containing 1% Nonidet P-40. Various concentrations of melanoma cell homogenates were used to make standard curves. GM3 melanoma antigens in the extracts were quantitated by RIA with 125 I-labeled M2590 anti-melanoma GM3 mAb as described (24, 25) .
51 Cr Release Cytotoxicity Assay. Target cells were labeled with 100 Ci sodium chromate (Amersham) per 5 ϫ 10 6 cells for 1 hr. ␣-GalCer-activated spleen cells from V␣14 NKT mice were used as effector cells and seeded into 96-well roundbottomed plates at the indicated effector͞target (E͞T) ratios on 51 Cr-labeled B16 melanoma cells (1 ϫ 10 4 ). Radioactivity released from lysed target cells was counted on a ␥-counter after 4 hr of incubation at 37°C in 5% CO 2 . The percentage of specific 51 Cr release was calculated by the following formula: % of specific lysis ϭ (sample cpm Ϫ spontaneous cpm) ϫ 100͞(maximum cpm Ϫ spontaneous cpm). Spontaneous cpm was calculated from the supernatant of the target cells alone, and the maximum release was obtained by adding 1 M HCl to target cells. The data are expressed as a mean value of triplicate cultures with standard deviations.
For cold target inhibition experiments, a mixture of ␣-GalCer-activated V␣14 NKT cells and Treatment of V␣14 NKT Cells with Concanamycin A (CMA). V␣14 NKT cells were preincubated with CMA (Wako Pure Chemical, Osaka) or control vehicle (dimethyl sulfoxide) at indicated concentrations as described (14, 27, 28) .
The assay was performed at an E͞T ratio of 50:1. Rausher virus-induced T cell lymphomas (RMA-S) and their CD1d-transfectants (RMA-S-CD1.1) were generated by L. Brossay, La Jolla Institute of Allergy and Immunology (La Jolla, CA).
RESULTS AND DISCUSSION
Antitumor Activity of V␣14 NKT Cells Activated by ␣-GalCer. The goal of this study was to clarify the effector mechanisms of the cytotoxic function of ligand-activated V␣14 NKT cells. Recently, we have identified ␣-GalCer as a ligand for the invariant V␣14 TCR exclusively expressed on V␣14 NKT cells (16) . To investigate effector function of ␣-GalCeractivated V␣14 NKT cells, we used three different types of mice: (i) wild-type mice bearing normal numbers of T cells, B cells, NK cells, and V␣14 NKT cells, (ii) V␣14 NKT-deficient mice that lack only V␣14 NKT cells while other lymphoid populations (T cells, B cells, and NK cells) remain intact (14) , and (iii) V␣14 NKT mice in which only V␣14 NKT cells but not T cells, B cells, or NK cells are present (16) .
We injected ␣-GalCer intraperitoneally after intrasplenic inoculation of B16 melanoma cells. The severity of melanoma metastasis was evaluated by measuring amounts of GM3 melanoma antigen in the liver. As shown in Fig. 1A , a negligible level of GM3 melanoma antigen was detected when ␣-GalCer but not vehicle was administrated in wild-type mice, indicating that ␣-GalCer treatment prevented liver metastasis of B16 melanoma almost completely. In contrast, the prevention of metastasis was not observed in V␣14 NKT-deficient mice lacking only V␣14 NKT cells. Because T cells and NK cells other than V␣14 NKT cells are generated normally in V␣14 NKT-deficient mice (14) , the antitumor effect by ␣-GalCer treatment appeared to be a consequence of the defect of V␣14 NKT cells. In V␣14 NKT mice bearing only V␣14 NKT cells without other lymphoid cells, as anticipated, the in vivo administration of ␣-GalCer suppressed the metastasis of B16 melanoma cells as effectively as observed in wild-type mice. Because the number of V␣14 NKT cells in the spleen of V␣14 NKT mice (7-9 ϫ 10 5 ) is similar to that in the wild-type mice (6-9 ϫ 10 5 ), the efficacy of tumor-killing activity appears to be equivalent. Fig. 1B shows representative photographic views of the metastasized livers. The metastatic melanoma nodules were visible as large black spots, which are not observed in the liver of either wild-type or V␣14 NKT mice if treated with ␣-GalCer. These results strongly suggest that the V␣14 NKT cells were selectively activated by ␣-GalCer and revealed an inhibitory effect on tumor metastasis in the liver. Similar in vivo effects of ␣-GalCer-mediated protection of tumor metastasis were observed in other tumor systems, such as Lewis lung carcinoma, erythroleukemia (FBL-3), Colon26, or RMA-S tested so far (data not shown).
As shown in Fig. 2 , cytotoxic activity against B16 melanoma was detected in vitro when V␣14 NKT mice were injected with ␣-GalCer but not with vehicle, indicating that ␣-GalCer-activation is required for mediating effector func- tion of V␣14 NKT cells. These findings confirm the in vivo data on the rejection of melanoma after administration of ␣-GalCer. NK-Like Effector Function of ␣-GalCer-Activated V␣14 NKT Cells. Next, we performed a series of experiments aimed at elucidating the molecular mechanism involved in the effector cytotoxic function of the ␣-GalCer-activated V␣14 NKT cells. Fig. 3A demonstrates a representative result of a cold target inhibition assay on B16 melanoma cell killing by ␣-GalCer-activated V␣14 NKT cells.
51
Cr release was reduced significantly by the addition of nonlabeled B16 melanoma cells in a dose-dependent manner, but not by EL-4, which is not susceptible to V␣14 NKT cell-mediated target cell lysis, indicating the requirement of direct cell-tocell contact. In addition, the treatment of V␣14 NKT cells with CMA inhibited antitumor cytotoxic activity of the ␣-GalCer-induced V␣14 NKT cells in a dose-dependent fashion (Fig. 3B) . Because CMA is a specific inhibitor of vacuolar-type H ϩ -AT Pase and inhibits the perforinmediated killing but not Fas-dependent cytotoxic pathway (27, 28) , the effector function of V␣14 NKT cells appeared to be mediated by NK-like mechanisms.
We tried to identify the cell surface molecule essential for direct cell contact involved in the cytotoxic interactions by using various mAbs with a specific blocking activity (Fig.  4A) . Interestingly, however, no significant inhibition was observed by the addition of mAbs specific for Fas ligand, Fas, Ly49C, NK1.1, TCRV␤8, CD1d, H-2D
The data shown in Fig. 4B in part confirm the results in Fig. 4 A on the nonessential requirement of CD1d͞invariant V␣14 TCR interactions in the effector phase. The ␣-GalCer-activated V␣14 NKT cells killed both RMA-S and RMA-S-CD1.1 cells, regardless of their CD1d expression or their antigen pulse with ␣-GalCer, confirming that the invariant V␣14͞ V␤8.2 TCR is not used in the cytotoxic interaction between V␣14 NKT cells and tumor target cells. The system appeared not to involve either Ly49C͞NK1.1 molecules essential for conventional NK cell-mediated killing or TCR͞MHC class I molecules necessary for CTL-mediated killing mechanisms. In particular, nonactivated V␣14 NKT but not NK cells killed FBL-3 tumor cells expressing MHC class I molecules on the target cell surface (Fig. 5) . It is well documented that NK cells killed only MHC class I negative target cells because of their negative signal through interaction of Ly49C molecule on NK cells with MHC class I molecule on target cells (29) . Therefore, V␣14 NKT cells killed the target in the different mechanisms from those of NK-mediated cytolysis. These results indeed are in agreement with the effector cytotoxic mechanisms of IL-12-activated V␣14 NKT cells against tumor cells (14) , suggesting that the ␣-GalCeractivated V␣14 NKT cells use a novel effector system mediating antitumor cytotoxicity. Although we could not block cytotoxic activity by the addition of antibodies against interferon ␥ (data not shown) or Fas ligand (see Fig. 4 A) , it is still possible that some cytokines are involved in the effector killing mechanisms.
In the present study, we demonstrated a unique feature of molecular requirements in activation and effector function of V␣14 NKT cells. Similar to the activation of conventional T cells, the specific ligand recognition by TCR is required for the activation of V␣14 NKT cells. The invariant V␣14 TCR recognizes ␣-GalCer presented by a CD1d molecule and mediates activation signals to V␣14 NKT cells together with costimulatory signals generated by B7͞CD28 and CD40͞ CD40 ligand interactions between dendritic cells and V␣14 NKT cells. Interestingly, however, the activated V␣14 NKT cells kill tumor targets by NK-like mechanisms in a nonspecific TCR-independent fashion. Because ␣-GalCer so far has not been detected on tumor target cells, it is necessary to provide a ligand stimulation through dendritic cells to activate V␣14 NKT cells. Once they are activated, they express nonspecific cytotoxic functions against a variety of tumors. In light of the successful control of V␣14 NKT cell activation in vivo, ␣-GalCer is an ideal drug to manipulate tumor eradication. 95 (1998) 
